Friday, May 12, 2023 12:04:01 PM
https://www.barchart.com/stocks/quotes/howl/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100
https://www.barchart.com/stocks/quotes/howl/opinion
Recent HOWL News
- Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting • GlobeNewswire Inc. • 10/04/2024 01:00:00 PM
- Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/03/2024 12:00:00 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 08/08/2024 11:21:26 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 11:12:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:07:30 AM
- Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/08/2024 11:05:00 AM
- Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma • GlobeNewswire Inc. • 06/25/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 11:56:58 AM
- Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors • GlobeNewswire Inc. • 06/01/2024 01:00:00 PM
- Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 08:27:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 11:52:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 11:48:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 11:46:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/24/2024 11:44:22 PM
- Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:00:00 PM
- Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/03/2024 11:00:00 AM
- Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 04/24/2024 02:05:00 PM
- Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting • GlobeNewswire Inc. • 04/05/2024 08:30:00 PM
- Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting • GlobeNewswire Inc. • 04/04/2024 08:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 12:22:36 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 12:15:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 12:11:06 PM
- Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/07/2024 12:00:00 PM
FEATURED Element79 Gold Corp Shares Further Advances With Chachas Community on Lucero Surface Rights, Provides Corporate Update • Oct 28, 2024 10:25 AM
VAYK Clarifies It Has No Business Connection to Persons Under SEC Charge • VAYK • Oct 28, 2024 11:59 AM
Vocodia Enters Medical Alert Industry with Innovative Emergency Response Pendant • VHAI • Oct 25, 2024 8:00 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for Third Quarter 2024 • HYDI • Oct 24, 2024 11:18 AM
VAYK Asserts Goal of Q4 Operationally Profitable and Projects Major 2025 Launch • VAYK • Oct 24, 2024 10:40 AM
CBD Life Sciences Inc. (CBDL) Positioned for Significant Growth Amid Nationwide Marijuana Legalization Push • CBDL • Oct 24, 2024 7:07 AM